RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) saw a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 554,532 shares, a drop of 53.0% from the June 15th total of 1,180,532 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.
RemeGen Price Performance
Shares of REGMF stock remained flat at $9.50 on Tuesday. RemeGen has a fifty-two week low of $9.50 and a fifty-two week high of $15.91. The stock’s 50-day moving average price is $10.62 and its 200-day moving average price is $10.42.
RemeGen Company Profile
RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.
RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.
Featured Stories
- Five stocks we like better than RemeGen
- The Bond Market Just Sent Amazon a Message Investors Shouldn’t Ignore
- Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings
- Insiders Sell 2 AI Enablers: Investors Can Buy Into Their Futures
- Beyond the Foundry: 5 Infrastructure Stocks Tackling the AI Bottlenecks
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
